Sun Pharma Advanced Research Company (SPARC) on Tuesday said the US health regulator has not approved its new drug application for Taclantis, its under development product for treatment of breast cancer.
"The company has received a Complete Response Letter (CRL) from the United States Food & Drug Administration (USFDA) for the new drug application (NDA) for Taclantis (Paclitaxel Injection Concentrate for Suspension)," SPARC said in a regulatory filing.
SPARC is reviewing the CRL and intends to work with the USFDA as soon as possible to address the concerns raised, it added.
As per the USFDA, a CRL is sent to an applicant if the agency determines that it will not approve the application or abbreviated application in its present form.
On July 1 last year, the company had announced that the USFDA had accepted for review SPARC's NDA for Taclantis.
The company's NDA filing was based on successful demonstration of clinical bioequivalence of Taclantis with Abraxane and associated clinical safety data.
Abraxane is indicated for treatment of breast cancer, lung cancer among others.
In 2017, USFDA had denied approval to SPARC's new drug application for Elepsia XR, an anti-epileptic drug.
Shares of SPARC on Tuesday ended 3.63 per cent lower at Rs 191.15 apiece on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
